Media

NEW YORK, NY–(Marketwired – Jan 24, 2014) – SmartMetric, Inc. (OTCQB: SMME), a developer of patented payment card technologies and in-card biometric products, announced today that the Company’s SmartMetric Intelligent Card OS™ sub-micro operating system for nano-computers is a powerful new technology platform for Bitcoin developers and entrepreneurs. The newly released operating system opens a world of possibilities for the creation of new Bitcoin products, services and apps that can run a device the size of a payment card.

SmartMetric recently announced the completion and availability of the SmartMetric Intelligent Card OS™, an operating system that runs on nano-computers built into its patented SmartMetric Biometric Bitcoin Card™. The card is the first biometric, fingerprint protected Bitcoin payment card in the world.

“SmartMetric is at the intersection of where nano-computing hardware and its accompanying software intersect with digital and crypto-currencies. Bitcoin is the clear early leader in this new digital currency arena and we believe SmartMetric’s payment card-based operating software is the first platform to enable exciting Bitcoin technologies that run on secure nano-computers,” stated SmartMetric President and CEO Chaya Hendrick.

“The adoption of Bitcoin is driven by the number of new Bitcoin-based products and services that improve our current financial system. We believe that our patented SmartMetric Biometric Bitcoin Card and our SmartMetric Intelligent Card OS™ can accelerate Bitcoin on its path to becoming a broadly used global currency,” Hendrick concluded.

Bitcoin product, service and app developers interested in creating new Bitcoin products for SmartMetric Intelligent Card OS may contact: chaya@smartmetric.com.

About SmartMetric Intelligent Card OS™

SmartMetric’s operating system is designed to run on SmartMetric intelligent cards, which combine biometrics with patented nano-computing technology, the world’s smallest fingerprint reader, an internal ARM 9 processor, processing power equal that of a PC, and up to 128 gigabytes of memory, matching the maximum memory capacity of current iPads.

About SmartMetric Biometric Bitcoin Card™

The SmartMetric Biometric Bitcoin Card is the world’s first biometric, fingerprint secured, off-line storage platform for Bitcoins. The card offers the benefits of Bitcoin such as peer-to-peer transactions and card-to-card direct Bitcoin sending anywhere in the world, while enabling real-time, in-person standard payment transactions at merchants and compatibility with standard ATMs around the world. Advanced patented payments card technology combines with the world’s first fingerprint technology to use the cardholder’s unique biometrics to lock and unlock the SmartMetric Biometric Bitcoin Card, providing safety and discrete portability.

About SmartMetric

SmartMetric, Inc. (OTCQB: SMME) develops patented biometric technologies used for security and identification, including the world’s smallest fingerprint reader. The Company’s proprietary advanced miniature electronics technology uses sub-micro computers to create fingerprint and security applications that were not previously possible. The world’s smallest fingerprint reader is designed to fit inside standard payments cards as well as ID cards. Because of the miniature size of the electronics it is ideal for use in a broad array of products requiring an enhanced identification system. SmartMetric’s products include the SmartMetric Biometric Bitcoin Card™, the SmartMetric Intelligent Card OS™, and MedicalKeyring™ a medical emergency biometric card. For information on SmartMetric and its technology please go to www.smartmetric.com.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received approval from the Medicines and Medical Device Agency of Serbia to begin enrollment of subjects in its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Serbia is the 11th country from which approval to participate in the world’s largest Phase III trial for the treatment of head and neck cancer has been obtained. The clinical sites in Serbia are expected to become active in the next few weeks. Approximately 72 of the worldwide total of 880 patients for the study are expected to be enrolled in Serbia.

Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g. FDA) for use following completion of CEL-SCI’s clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body’s natural ability to fight tumors.

“Immunotherapy has come to be recognized as the next great breakthrough in cancer therapeutics. Science Magazine named cancer immunotherapy the Breakthrough of the Year for 2013. The magazine suggests that clinical trials have cemented immunotherapy’s potential in patients and swayed even the skeptics. Science Magazine also reports that oncologists say a corner has been turned and we won’t be going back. CEL-SCI has been an early participant in the study of cancer immunotherapeutics and it’s very exciting to see this class of cancer therapies acknowledged for its potential to transform the treatment of cancer,” stated CEL-SCI CEO Geert Kersten. “We are pleased to advance our Phase III trial, as Serbia becomes the latest country to participate in this important immunotherapy trial.”

To read the Science Magazine article in full, please visit: http://www.sciencemagazinedigital.org/sciencemagazine/20_december_2013?pg=28#pg28.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI’s Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

LAWRENCEVILLE, N.J., Jan. 21, 2014 /PRNewswire/ — Celsion Corporation (CLSN), a leading oncology drug development company, announced today that the company is formalizing a program to pursue the development of ThermoDox® to investigate applications for treating brain cancer tumors, notably Glioblastoma Multiforme or GBM. In addition to jointly submitting multiple grant applications, the company is also pursuing preclinical studies in collaboration with Dr. Costas D. Arvanitis at the Brigham and Women’s Hospital and Harvard Medical School. Experiments will study the use of ThermoDox in combination with MR guided High Intensity Focused Ultrasound (HIFU) to treat brain tumors, initially in animal models.

“Brain cancer tumors represent a very high unmet medical need, and researchers have been pursuing applications with HIFU for many years,” said Nicholas Borys, MD, Celsion’s Chief Medical Officer. “We are excited to investigate the addition of ThermoDox, our heat-activated liposomal encapsulation of doxorubicin, which could provide some clinical benefit for a population that desperately needs more applications.”

Dr. Arvanitis, research fellow at Brigham and Women’s Hospital and Harvard Medical School stated, “We have investigated the use of MR-guided focused ultrasound to treat brain tumors for many years and have identified the need for drugs that will improve our ability to treat brain tumors. We are excited about this drug design, which is positioned to work with heat and specifically HIFU, and its potential to cross the blood-brain barrier and potentially demonstrate drug concentration in ways that other drugs cannot. We are grateful for Celsion’s support in this research and look forward to pursuing this initial, pre-clinical research with the hope of bringing this application to the clinic in the future.”

About Glioblastoma Multiforme (GBM) Brain Tumors

Glioblastoma multiforme (GBM), WHO classification name “glioblastoma”, is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for over 50% of all functional tissue brain tumor cases and nearly 20% of all intracranial tumors. In 2013, projected US incidence of brain tumors approaches 23,000 cases, with projected mortality at 14,000. Treatment can involve chemotherapy, radiation and surgery. Median survival with standard-of-care radiation and chemotherapy is normally 15 months, and Median survival without treatment is approximately 4½ months.

About ThermoDox®

ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox® is administered intravenously in combination with RFA. Localized mild hyperthermia (39.5 – 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a 701 patient global Phase III study at 79 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone as the control. On January 31, 2013, Celsion announced that ThermoDox® in combination with RFA did not meet the primary endpoint of the HEAT study in patients with hepatocellular carcinoma, also known as primary liver cancer. Celsion has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts. Emerging data from the HEAT Study post hoc analysis demonstrates that ThermoDox® markedly improves PFS and overall survival in patients if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of approximately 300 patients.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

HAIFA, Israel, Jan. 23, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell product candidates, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), Germany’s health authority, to supply cells from its advanced, fully automated, and proprietary 3D cell expansion manufacturing platform implemented at its new state-of-the-art GMP facility. Pluristem’s new manufacturing facility has the capability to efficiently produce over 150,000 doses of PLX cells annually, which potentially translates into significant economic value.

This marks the first regulatory approval of Pluristem’s new facility where the company has implemented its large scale 3D bioreactor expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs). The approval will enable the company to easily support ongoing trials and enter into multiple clinical trials using its scale-up capabilities for cell supply. The company is also in the process of getting approvals from other regulatory authorities including the US FDA.

“We are very pleased to receive the PEI’s approval. Following our multi-million dollar investment into the development of our proprietary high-throughput culturing technologies, 3D bioreactors, and proprietary downstream equipment, the PEI’s approval confirms Pluristem’s unique position in the cell therapy industry. Our proprietary 3D manufacturing process can create commercial quantities of cells with batch-to-batch consistency, so we are ready to expand and accelerate our clinical programs,” stated Zami Aberman, Chairman and CEO of Pluristem. “In addition, the very encouraging results of our Phase I/II trial in muscle injury conducted in Germany suggest that our unique culturing technology may contribute to the quality and consistency of PLX clinical studies.”

About Pluristem’s 3D Manufacturing

Pluristem’s state-of-the-art manufacturing site is located in MATAM industrial park, in Haifa, Israel and is equipped with 500 square meters of clean rooms in which cells can be manufactured to support clinical trials and for commercial demand at time of regulatory approval. Pluristem develops and manufactures its products in full compliance with international quality standards, including U.S. Food and Drug Administration (FDA), European Medicines Agencies (EMA), current Good Manufacturing Practices (cGMP) requirements and International Conference on Harmonization (ICH) quality guidelines. Pluristem believes that controlling the process is the key to success and therefore invests major efforts in developing highly efficient, cutting-edge culturing systems enabling advancement of its large PLX cell therapy product candidate’s pipeline.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

NEW YORK, NY–(Marketwired – Jan 22, 2014) – SmartMetric, Inc. (OTCQB: SMME), a developer of patented payment card technology and in-card biometric products, announced today that it has created a sub-micro operating system for nano-computers. The SmartMetric Intelligent Card OS™ is an operating system that unlocks new possibilities for software and app development for a payment card-sized device that has broad functionality, comparable to a smartphone or tablet.

“We’ve seen the evolution of computing move from mainframe, to PC, to tablets, and then to smartphones. Now, SmartMetric is leading the next wave of miniaturization with our SmartMetric intelligent card. Combining our patented nano-computing hardware with our sub-micro operating system, we believe we’ve created the next new device of the future and it’s the size of a payment card,” stated SmartMetric President and CEO Chaya Hendrick.

SmartMetric’s operating system is designed to run on the SmartMetric intelligent card, which combines biometrics with patented nano-computing technology, the world’s smallest fingerprint reader, an internal ARM 9 processor, processing power equal that of a PC, and up to 128 gigabytes of memory, matching the maximum memory capacity of current iPads.

Powered by SmartMetric’s operating system, developers can now create never before possible apps that run on a payment card, for a broad range of functions including gaming, security, consumer, and industrial. Developers interested in creating apps for the SmartMetric card may contact: chaya@smartmetric.com.

About SmartMetric

SmartMetric, Inc. (OTCQB: SMME) develops patented card technologies used for payments, security and identification, including the world’s smallest in-card fingerprint reader. The Company’s proprietary advanced miniature electronics technology uses sub-micro computers to create fingerprint and security applications that were not previously possible. The world’s smallest fingerprint reader is designed to fit inside standard payments cards as well as ID cards. Because of the miniature size of the electronics it is ideal for use in a broad array of products requiring an enhanced identification system. SmartMetric’s products include biometric credit card and biometric debit card technologies, a medical emergency biometric card, and a MedicalKeyring™. For information on SmartMetric and its technology please go to www.smartmetric.com.

WILMINGTON, Mass., Jan. 21, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has joined the American Association of Airport Executives (AAAE). AAAE is the world’s largest professional organization for airport executives, representing thousands of airport management personnel at public-use commercial and general aviation airports. The organization’s members represent approximately 850 airports and hundreds of companies and organizations that support airports.

“We are continuing to progress through the TSA checkpoint qualification process for our QS-B220. When we have completed this, we believe we will be in a prime position to have our next-generation ETDs installed in airports in the U.S. Our membership in AAAE will facilitate the communication of the value-proposition that Implant Sciences’ next generation ETD provides to both airports and travelers,” stated Implant Sciences’ President and CEO, Glenn D. Bolduc.

“Collaboration between airport executives and proven technology providers like Implant Sciences is critical to our ongoing efforts to enhance security and efficiency in the airport environment,” AAAE President and CEO, Todd Hauptli, commented. “We appreciate the value that Implant Sciences sees in having an opportunity to engage and work with our members, and we welcome them into the AAAE family.”

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company’s QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

HAIFA, Israel, Jan. 21, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced top-line results from its Phase I/II clinical trial testing the safety and efficacy of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury. The trial indicated PLX-PAD cells were safe and statistical significance was reached (p=0.0067) for the primary efficacy endpoint of the study, the change in maximal voluntary isometric contraction force of the gluteal muscle at six months after total hip replacement. Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group. These results provide evidence that PLX cells may be efficacious in the treatment of orthopedic injuries including muscles and tendons.

This Phase I/II trial was a randomized, placebo-controlled, double-blinded study conducted at the Orthopedic Clinic of the Charite University Medical School under the auspices of the Paul-Ehrlich-Institute (PEI), Germany’s health authority. The injured muscle studied was the gluteus medius muscle in the buttock. Total hip replacement surgery via the standard transgluteal approach necessitates injury of the gluteus medius muscle, and post-operative healing is crucial for joint stability and function.

The 20 patients in the study were randomized into three treatment groups. Each patient received an injection in the gluteal muscle that had been traumatized during surgery. One group was treated with 150 million PLX-PAD cells per dose (n=7), the second was administered 300 million PLX-PAD cells per dose (n=6), and the third received placebo (n=7).

The primary safety endpoint was clearly met, with no serious adverse events reported at either dose level. The study showed that PLX-PAD cells were safe and well tolerated.

The primary efficacy endpoint of the study was the change in maximal voluntary isometric contraction force of the gluteal muscle at six months post-surgery. Efficacy was shown in both PLX-PAD treated patient groups, with the group receiving the 150 million cell dose displaying a statistically significant 500% improvement over the placebo group in the change of the maximal contraction force of the gluteal muscle (p=0.0067). Patients treated at the 300 million cell dose showed a 300% improvement over the placebo (p=0.18).

An analysis of the macrostructure of the gluteal muscle using magnetic resonance imaging (MRI) indicated an increase in muscle volume in those patients treated with PLX-PAD cells versus the placebo group. This efficacy endpoint was demonstrated in both PLX-PAD treated patient groups, with the group receiving the 150 million cell dose displaying a statistically significant superiority over the placebo group. Patients treated at the 150 million cell dose showed an approximate 300% improvement over the placebo in the analysis of muscle volume (p=0.004). Patients treated at the 300 million cell dose showed an approximate 150% improvement over the placebo in the change of muscle volume (p=0.19). The complete dataset that includes biopsy results and functional assessments will be presented at a medical conference once the final analyses are completed.

The study’s Senior Scientist, Dr. Tobias Winkler of the Center for Musculoskeletal Surgery, Julius Wolff Institute Berlin, Charite — Universitaetsmedizin Berlin, Germany, commented, “I am very impressed with the magnitude of the efficacy results seen in this trial. PLX cells demonstrated safety and suggested that the increase in muscle volume could be a mechanism for the improvement of contraction force.”

Zami Aberman Chairman and CEO stated, “This was a very important study not only for Pluristem but for the cell therapy industry in general. The study confirms our pre-clinical findings that PLX-PAD cell therapy can be effective in treating muscle injury. Having a statistically significant result for our primary efficacy endpoint is very encouraging and consistent with our understanding of the mechanism of action associated with cell therapy. Based on these results, we intend to move forward with implementing our strategy towards using PLX cells in orthopedic indications and muscle trauma.”

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication.

The Phase IIa Archexin proof-of-concept clinical trial is a multi-center study designed to evaluate the efficacy of Archexin in combination with everolimus (Afinitor®) to treat metastatic RCC patients and will be conducted in two stages. Stage 1 will be dose ranging with up to 3 cohorts of 3 RCC patients to determine its maximum tolerated dose in combination with everolimus. Based on previous clinical data the target dose of Archexin is anticipated to be no more than 250 mg/m2 per day. The decision to enroll the next group of patients and escalate the dose will be made after completion of the first 21 day cycle of treatment. Patient assessments will include safety, pharmacokinetics, laboratory and physical exams. Once the maximum tolerated dose of Archexin in combination with everolimus has been determined, thirty RCC patients will be randomized to either Archexin in combination with everolimus or everolimus alone, in a ratio of 2:1.

The primary endpoint will be the percentage of progression free patients following eight cycles of therapy. Patients will be scanned (CT or MRI) for the assessment of tumor progression after every 2 cycles of therapy. Secondary endpoints include pharmacokinetic profile, incidence of adverse events, changes in clinical laboratory tests and vital signs over time, tumor response, duration of response, time to response, and response rate. Exploratory endpoints will include blood levels of AKT pathway biomarkers, tumor apoptosis biomarkers or other relevant biomarkers.

Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer commented, “The start of the Phase IIa clinical-proof-of-concept trial in RCC patients represents an important milestone for the Archexin clinical development program. The combination of strong scientific data, unmet clinical need, and our Orphan Drug Designation were all driving factors for choosing this indication.”

Archexin is a specific inhibitor of the cancer cell signaling protein Akt-1. The activated form of Akt-1 (phospho-Akt-1) has been shown to be involved in cancer cell growth, survival, angiogenesis, and drug resistance. Phospho-Akt-1 has been shown to be significantly increased in more than 12 different human cancer cell lines including human renal cell carcinoma cells. Archexin has shown to inhibit the growth of human RCC cells in tissue culture and produce a substantial survival benefit in animal xenograft models of RCC. Archexin also exhibits additive anti-tumor effect when combined with other cancer drugs in inhibiting the growth of human RRC cells in tissue culture. In addition, resistance to the anti-cancer effects of clinically used mTOR inhibitors such as everolimus (Afinitor®), which is used as second line therapy in RCC patients, has been attributed to an increase in Akt-1 activity. Thus, treatment with Archexin may both inhibit the growth/proliferation of RCC and overcome the resistance to mTOR inhibitors such as everolimus, resulting in an increase in efficacy.

Dr. Neeraj Agarwal MD, Director, GU Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, “The treatment of patients with metastatic RCC remains a significant unmet medical need. Selective Akt-1 inhibition represents a very promising new mechanism for the treatment of metastatic RCC. The potential to both inhibit the growth of RCC cells and affect the underlying mechanism responsible for the development of tolerance to second line therapies such as everolimus is very promising.”

NEW YORK, NY–(Marketwired – Jan 14, 2014) – SmartMetric, Inc. (OTCQB: SMME), a developer of patented payment card technology and in-card biometric products, announced today that its soon-to-launch SmartMetric Biometric Bitcoin Card, the world’s first biometric, fingerprint secured, off-line storage platform for bitcoins, will enable in-person Peer-to-Peer (P2P) transfer of bitcoins through its payment card.

“We believe our card will be the world’s first to enable in-person, P2P transfer of bitcoins through a payment card. This is made possible by our patented nano-computing technology that puts the power of PC’s computing capacity onto a payment card. Bitcoins can be stored and transferred, all on the card, and with a level biometric fingerprint security never before possible. We’re very excited about the possibilities for bitcoin use and adoption powered by SmartMetric’s nano-computing and biometric security capabilities,” stated SmartMetric President and CEO Chaya Hendrick.

The SmartMetric Biometric Bitcoin Card has taken a quantum leap beyond smartcards. This is an intelligent card that combines patented nano-computing technology, an internal ARM 9 processor, processing power equal that of a PC, and up to 128 gigabytes of memory, matching the maximum memory capacity of current iPads.

The card comes equipped with a Near Field Communication (NFC) chip, which is the key to enabling the in-person P2P transaction. NFC chips are used in smartphones and similar devices to establish radio communication with each other by touching them together or bringing them into proximity. Cards are able to be connected to a computers USB or following the fingerprint scan and subsequent activation of the NFC (Near Field Communication) chip following the match of the card holders fingerprint, the SmartMetric bitcoin card can communicate directly with NFC smartphones and tablets. In order to protect the card owners privacy their fingerprint is stored inside the card and never leaves the card.

Bitcoins have grown to a global circulation of $11 billion driven by the digital currency’s appeal as a P2P currency without a central bank, financial institution, or central server at its core. SmartMetric takes bitcoin one step further by enabling in-person P2P transfers through a payment card. The SmartMetric Biometric Bitcoin Card is slated for launch during the first quarter of 2014.

About SmartMetric Biometric Bitcoin Card

The SmartMetric Biometric Bitcoin Card is the world’s first biometric, fingerprint secured, off-line storage platform for bitcoins. The card offers the benefits of bitcoins such as peer-to-peer transactions and card-to-card direct bitcoin sending anywhere in the world, while enabling real-time, in-person standard payment transactions at merchants and compatibility with standard ATMs around the world. Advanced patented payments card technology combines with the world’s first fingerprint technology to use the cardholder’s unique biometrics to lock and unlock the SmartMetric Biometric Bitcoin Card, providing safety and discrete portability.

WILMINGTON, Mass., Jan. 14, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that Mercury Air Cargo, a division of the Mercury Air Group, has placed a follow-on order for the QS-B220™ desktop explosives trace detector (ETD), after having already purchased and deployed the QS-B220 in June. Mercury is deploying its QS-B220 systems at its air cargo screening facility at Los Angeles International Airport, one of the highest volume airports in the world.

“At Mercury Air Cargo, we are honored to work with some of the biggest names in the sky. These companies look to us because of our strong reputation and experience in cargo handling and screening. As such, having an ETD system that provides a low-cost, easy-to-use solution is of the utmost importance,” said Darrin Naughton, ICSF Cargo Security Manager at Mercury Air Cargo. “We are pleased to work with Implant Sciences, and have been impressed by their training, service, and support team.”

“Having a non-radioactive source was another important factor for Mercury and our QS-B220 is the only TSA-qualified ETD that offers this benefit. The ease of use and smaller number of consumables required relative to competing products were other factors that drove the customer’s repeat purchase decision,” commented Implant Sciences’ VP of Sales and Marketing, Darryl Jones. “We look forward to a long-term relationship with Mercury Air Cargo.”

Mercury Air Cargo is a TSA Certified Cargo Screening Facility (CCSF), and as such is required to use TSA qualified systems when screening air cargo packages for explosives before they are loaded onto airplanes.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company’s QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. For further details on the Company and its products, please visit the Company’s website at http://www.implantsciences.com.